Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data

por Aslaner Ak, Müzeyyen, Gedük, Ayfer, Acar, İbrahim Halil, Polat, Merve Gökçen, Sunu, Cenk, Bolaman, Ali Zahit, Hacıbekiroğlu, Tuğba, Güvenç, Birol, Ertop, Şehmus
Publicado 2023